Japan Tissue Engineering Co., Ltd.
7774・Growth Market・Precision Instruments
Regenerative Medicine Products Business
Core business holding five products including Japan's first regenerative medicine products
| Period | Current | Previous | Change |
|---|---|---|---|
| Segment revenue (full year, FY2026 ending March 2026) | ¥1,354 million | ¥1,493 million | ↓ |
| Segment profit (full year, FY2026 ending March 2026) | ¥78 million | ¥219 million | ↓ |
| Segment assets (as of end of March 2026) | ¥1,236 million | ¥1,288 million | ↓ |
| Depreciation (full year, FY2026 ending March 2026) | ¥65 million | ¥66 million | — |
| Year-over-year revenue change rate (FY2026 ending March 2026) | △9.3% | – | ↓ |
Business Details
This segment manufactures and sells five products to medical institutions: JACE (Autologous Cultured Epidermis) for skin, JACC (Autologous Cultured Cartilage) for cartilage, Nepic (Autologous Cultured Corneal Epithelium) for cornea, Ocural (Autologous Cultured Oral Mucosal Epithelium) for cornea, and JASMIN (Melanocyte-containing Autologous Cultured Epidermis) for skin. The business is based on the autologous transplantation method, in which a patient's own cells are cultured and transplanted, and provides insurance-covered products that have received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare. In FY2026 (ending March 2026), this segment accounted for approximately 62% of total company revenue of ¥2,183 million, making it the core segment.
Recent Overview
Sharp increase in JACC orders toward year-end following insurance listing for knee osteoarthritis, but overall revenue declined
Regenerative Medicine Products Business revenue for FY2026 (ending March 2026) was ¥1,354 million (down 9.3% year on year). This was impacted by a continued decline in the number of burn patients and sluggish growth in new patients in the corneal field. On the other hand, following the insurance listing of JACC for knee osteoarthritis in January 2026, the number of contracted facilities expanded to 125, and a record monthly high of 30 cases was achieved in March. JASMIN also built a foundation for revenue growth by expanding its network of participating facilities to 42. Segment profit fell sharply to ¥78 million from ¥219 million in the prior period.
Key Products
Growth Drivers
- Market expansion and increase in contracted facilities (125 facilities) driven by the insurance listing of JACC for knee osteoarthritis (January 2026), along with a record high in monthly orders
- Building a foundation for revenue growth through the expansion of JASMIN's participating facilities (42 facilities) and securing orders from new facilities
- Future expansion of the product lineup and overseas development through the application for manufacturing and marketing approval of allogeneic cultured epidermis (Allo-JaCE03) (March 2026)
- Progress in the joint development of new knee-field products with Teijin
- Development of new facilities and promotion of treatment awareness among potential patients for corneal field products in collaboration with Nidek
Risks
- Structural cost challenges due to the nature of the autologous transplantation method, which requires individualized manufacturing for each patient and makes it difficult to achieve economies of scale
- Slowing demand due to a decline in and saturation of the target patient population for existing indications such as burns, giant congenital melanocytic nevus, and epidermolysis bullosa
- Continued sluggish growth in new patients and declining orders at existing facilities for corneal field products (Nepic and Ocural)
- Risk that the pace of adoption of JACC for knee osteoarthritis following insurance listing may fall short of expectations
- Risk of changes in the regulatory environment, including discussions on reviewing the conditional and time-limited approval system
Last updated: June 18, 2026